King's College London

Research portal

Drugs for metabolic conditions and prostate cancer death in men on GnRH agonists

Research output: Contribution to journalArticle

Cecilia Bosco, Chloe Wong, Hans Garmo, Danielle Crawley, Lars Holmberg, Niklas Hammar, Jan Adolfsson, Pär Stattin, Mieke Van Hemelrijck

Original languageEnglish
JournalBJU International
Early online date17 Oct 2017
Publication statusE-pub ahead of print - 17 Oct 2017


  • GnRHpCadeath12July_withTC

    GnRHpCadeath12July_withTC.docx, 957 KB, application/vnd.openxmlformats-officedocument.wordprocessingml.document


    Submitted manuscript

King's Authors


Objective: To evaluate whether drugs for metabolic conditions influence prostate cancer-specific mortality in men starting gonadotrophin-releasing hormone (GnRH) agonists, as it is unclear whether metabolic syndrome and its related drugs is affecting treatment response in men with prostate cancer on GnRH agonists. Patients and Methods: We selected all men receiving GnRH agonists as primary treatment in the Prostate Cancer data Base Sweden (PCBaSe) (n = 9267). Use of drugs for metabolic conditions (i.e. anti-diabetes, anti-dyslipidaemia, and antihypertension) in relation to all-cause, cardiovascular disease (CVD), and prostate cancer-specific death were studied using multivariate Cox proportional hazard and Fine and Gray competing regression models. Results: In all, 6322 (68%) men used at least one drug for a metabolic condition at GnRH agonist initiation: 46% on antihypertensive drugs only, 32% on drugs for dyslipidaemia and hypertension, and ~10% on drugs for more than two metabolic conditions. Cox models indicated a weak increased risk of prostate cancer death in men who were on drugs for hypertension only (hazard ratio [HR] 1.12, 95% confidence interval [CI] 1.03-1.23) or drugs for hyperglycaemia (HR 1.19, 95% CI 1.06-1.35) at GnRH agonist initiation. However, upon taking into account competing risk from CVD death, none of the drugs for metabolic conditions were associated with an increased risk of prostate cancer death. Conclusion: We did not find evidence for a better or worse response to GnRH agonists in men with prostate cancer who were also on drugs for hypertension, dyslipidaemia, or hyperglycaemia.

Download statistics

No data available

View graph of relations

© 2018 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454